Overview
Epirium Bio is a clinical-stage biopharmaceutical company developing orally bioavailable small-molecule therapeutics that modulate PGE-2 signaling to restore tissue homeostasis and promote regeneration. The company targets neuromuscular diseases, particularly sarcopenia, as well as inflammatory and fibrotic conditions including spinal muscular atrophy, irritable bowel disease, and idiopathic pulmonary fibrosis. Epirium Bio's lead candidate, MF-300, a first-in-class 15-PGDH enzyme inhibitor, is advancing through Phase 2b clinical development for sarcopenia, with the company pursuing a therapeutic approach aimed at addressing age-related muscle wasting and tissue dysfunction.